Boster Biological Technology advances biotechnology research with its cutting-edge multiplex ELISA service, delivering ...
Zacks Small Cap Research on MSN4h
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...
AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered ...
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination ...
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Stifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy ...
In a report released today, Soumit Roy from JonesTrading initiated coverage with a Buy rating on Mural Oncology Plc (MURA – Research Report) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback